DNLI
Price
$20.21
Change
-$1.07 (-5.03%)
Updated
Feb 5, 02:42 PM (EDT)
Capitalization
3.32B
25 days until earnings call
Intraday BUY SELL Signals
LYEL
Price
$23.15
Change
-$1.03 (-4.26%)
Updated
Feb 5, 03:19 PM (EDT)
Capitalization
509.22M
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs LYEL

Header iconDNLI vs LYEL Comparison
Open Charts DNLI vs LYELBanner chart's image
Denali Therapeutics
Price$20.21
Change-$1.07 (-5.03%)
Volume$125
Capitalization3.32B
Lyell Immunopharma
Price$23.15
Change-$1.03 (-4.26%)
Volume$100
Capitalization509.22M
DNLI vs LYEL Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
LYEL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. LYEL commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and LYEL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (DNLI: $21.28 vs. LYEL: $24.18)
Brand notoriety: DNLI and LYEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 107% vs. LYEL: 111%
Market capitalization -- DNLI: $3.32B vs. LYEL: $509.22M
DNLI [@Biotechnology] is valued at $3.32B. LYEL’s [@Biotechnology] market capitalization is $509.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileLYEL’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • LYEL’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNLI and LYEL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while LYEL’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • LYEL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than LYEL.

Price Growth

DNLI (@Biotechnology) experienced а +2.11% price change this week, while LYEL (@Biotechnology) price change was +0.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.32B) has a higher market cap than LYEL($509M). DNLI YTD gains are higher at: 28.892 vs. LYEL (-21.442). LYEL has higher annual earnings (EBITDA): -188.82M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. LYEL (320M). LYEL (44.3M) and DNLI (44.4M) have identical debt. LYEL has higher revenues than DNLI: LYEL (41K) vs DNLI (0).
DNLILYELDNLI / LYEL
Capitalization3.32B509M653%
EBITDA-534.17M-188.82M283%
Gain YTD28.892-21.442-135%
P/E RatioN/AN/A-
Revenue041K-
Total Cash848M320M265%
Total Debt44.4M44.3M100%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
16
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLILYEL
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
LYEL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CNPSX72.391.36
+1.91%
Consumer Staples UltraSector ProFund Svc
WHGLX12.190.06
+0.49%
Westwood Quality Value Fund Inst
FCDCX37.17N/A
N/A
Fidelity Advisor Stock Selector Sm Cp C
MFCCX36.47-0.24
-0.65%
Meridian Contrarian C
BIOUX54.83-0.93
-1.67%
Baron Opportunity R6

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with NRIX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.30%
NRIX - DNLI
68%
Closely correlated
-1.43%
IMVT - DNLI
64%
Loosely correlated
-2.52%
ARWR - DNLI
63%
Loosely correlated
-5.66%
SYRE - DNLI
62%
Loosely correlated
-3.66%
ROIV - DNLI
59%
Loosely correlated
-1.46%
More

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
-6.17%
VCYT - LYEL
46%
Loosely correlated
-4.35%
TYRA - LYEL
44%
Loosely correlated
-1.50%
ERAS - LYEL
42%
Loosely correlated
+6.19%
DNLI - LYEL
39%
Loosely correlated
-2.30%
CGEM - LYEL
38%
Loosely correlated
-6.66%
More